Abwiz Bio remains open

At Abwiz Bio, we believe that our revolutionary recombinant rabbit monoclonal antibody platform RabWizTM can play a critical role in the development of next-generation COVID-19 diagnostic tools. We have multiple projects currently underway to develop highly-specific SARS-CoV-2 monoclonal antibodies for immediate diagnostic use and as potential therapeutic candidates. Not only are rabbit immunizations currently underway, but we are also fast-tracking construction of a naïve library that we believe can provide SARS-CoV-2 antibody lead candidates even faster than our typical immunization-based platform. Our work has been recognized in the FIND diagnostic registry under manual/automated immunoassays in development.


We believe that it is important to continue to support basic and translational research during this time. Our current contract services including affinity maturation and recombinant mAb development remain available and will be supported for the duration of the COVID-19 outbreak. Additionally, we believe that it is important to continue to support basic scientific research, especially during the emergence of a novel pandemic virus. Our research reagents remain available for purchase through our website and are packaged under strict clean and sterile conditions.


We will provide regular updates below for our COVID-19 diagnostic and therapeutic antibody development.

SARS-CoV-2 diagnostic mAb development

We are currently developing highly specific rabbit antibodies to create an antibody diagnostic test for active SARS-CoV-2 infections. We are targeting the nucleoprotein (NP) of SARS-CoV-2 to create novel antibodies that can discriminate this virus from closely-related cornaviruses. We have finished rabbit immunization and have confirmed strong and specific reactivity to multiple NP epitopes. Library construction is currently underway, to be followed by Fab-phage panning to select for lead candidates.

sars-cov-2 serum elisa
Peptide immunization of rabbit 23475 elicited a strong serum response, highly specific to SARS-CoV-2 (blue) compared to a related related SARS 2002 antigen (orange), that also recognized whole recombinant protein.

SARS-CoV-2 therapeutic mAb development

We are currently developing rabbit antibodies for use as therapeutic lead candidates to treat SARS-CoV-2 infection. We are targeting the receptor binding domain (RBD) of SARS-CoV-2 to create novel antibodies that can neutralize virus entry into host cells by blocking human ACE-2 receptor binding. Antigen preparation is currently underway, which will be followed by rabbit immunization to elicit high affinity rabbit antibodies.

Employee safety is a top priority

We believe that our employees are our greatest asset, and we would not ask them to take any unnecessary risks with their health. We are taking all possible precautions for our employees, including:

  • Continuing full pay and benefits, despite reduced company revenue
  • A dramatic reduction in on-site work hours
  • Limiting the number of employees on site at any given time
  • Closing employee recreational rooms and services
  • Limiting employee contact while in the office
  • Enforcing PPE policies while in common areas or working with shared equipment


Abwiz Bio intends to remain open and diligently working on projects for our client partners as well as for the general public. Please contact us to find out how we can support you and your team during this time of global pandemic.

coronavirus electron micrograph